These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22146226)

  • 1. Telaprevir: looking for a sustained virologic response in hepatitis C virus infection.
    Nehra V; Rizza SA; Talwani R; Temesgen Z
    Drugs Today (Barc); 2011 Nov; 47(11):829-37. PubMed ID: 22146226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J; Rivero A
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined telaprevir plus ribavirin and pegylated interferon therapy for patients with chronic hepatitis C].
    Mochida S
    Nihon Rinsho; 2015 Feb; 73(2):259-65. PubMed ID: 25764680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Burney T; Dusheiko G
    Expert Rev Anti Infect Ther; 2011 Feb; 9(2):151-60. PubMed ID: 21143041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
    Corti G; Salomoni E; Baragli F
    Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
    Foster GR; Hézode C; Bronowicki JP; Carosi G; Weiland O; Verlinden L; van Heeswijk R; van Baelen B; Picchio G; Beumont M
    Gastroenterology; 2011 Sep; 141(3):881-889.e1. PubMed ID: 21699786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possible telaprevir-induced pancreatitis. A case study].
    Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
    Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
    [No Abstract]   [Full Text] [Related]  

  • 17. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir for retreatment of HCV infection.
    Zeuzem S; Andreone P; Pol S; Lawitz E; Diago M; Roberts S; Focaccia R; Younossi Z; Foster GR; Horban A; Ferenci P; Nevens F; Müllhaupt B; Pockros P; Terg R; Shouval D; van Hoek B; Weiland O; Van Heeswijk R; De Meyer S; Luo D; Boogaerts G; Polo R; Picchio G; Beumont M;
    N Engl J Med; 2011 Jun; 364(25):2417-28. PubMed ID: 21696308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.